{
  "slug": "cisterna-biologics",
  "name": "Cisterna Biologics",
  "yc_id": 26554,
  "batch": "Summer 2022",
  "website": "http://www.cisternabx.com",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:16:26.492044",
    "website": "http://www.cisternabx.com",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 2898.29,
      "final_url": "https://www.cisternabx.com/",
      "redirected": true,
      "checked_at": "2025-10-17T01:16:29.390340"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "cisternabx.com",
      "registrar": "Squarespace Domains II LLC",
      "creation_date": "2022-05-10T19:03:35",
      "expiration_date": "2026-05-10T19:03:35",
      "domain_age_days": 1255,
      "domain_age_years": 3.4,
      "name_servers": [
        "NS-CLOUD-D1.GOOGLEDOMAINS.COM",
        "NS-CLOUD-D2.GOOGLEDOMAINS.COM",
        "NS-CLOUD-D3.GOOGLEDOMAINS.COM",
        "NS-CLOUD-D4.GOOGLEDOMAINS.COM"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": true,
      "content_security_policy": true,
      "x_frame_options": true,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 50,
      "server": "cloudflare"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:47.464021",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0-claude",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T10:52:59.412066",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "mRNA therapeutics expansion beyond vaccines",
        "increasing demand for high-quality mRNA manufacturing",
        "growing investment in RNA-based drug development"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary mRNA purification and manufacturing technologies addressing fundamental quality and cost challenges",
      "differentiation": "Focus on solving core mRNA production issues (quality, quantity, longevity, cost) rather than developing therapeutics",
      "competitive_advantages": [
        "Specialized expertise in mRNA contaminant removal",
        "B2B enabler model serving entire mRNA therapeutics industry"
      ],
      "competitive_vulnerabilities": [
        "Small team size for complex biotech challenges",
        "Dependence on mRNA market adoption rates"
      ]
    },
    "business_model": {
      "revenue_model": "B2B technology licensing/services",
      "scalability": "high",
      "capital_intensity": "medium"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Active status post-YC",
        "Established web presence",
        "Clear market need identification"
      ],
      "growth_bottlenecks": [
        "Limited team size",
        "Need for regulatory validation",
        "Customer acquisition in specialized market"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 7,
      "key_risks": [
        "Regulatory approval complexity",
        "Technical validation challenges",
        "Competition from established biotech companies"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Addresses critical industry pain points",
        "Enabler model with broad market applicability",
        "YC validation and network access"
      ],
      "concerns": [
        "Very small team for complex biotech venture",
        "High technical and regulatory barriers"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Moderna",
        "BioNTech",
        "CureVac"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Expand technical team",
        "Establish key industry partnerships"
      ],
      "expansion_opportunities": [
        "International mRNA manufacturing markets",
        "Adjacent RNA therapeutic applications"
      ]
    },
    "tokens_used": {
      "input": 741,
      "output": 562,
      "total": 1303,
      "estimated_cost": 0.010653
    },
    "status": "success"
  },
  "phase8_complete": true
}